Compare Gilead Sciences, Inc. (GILD) vs JPMorgan Diversified Return International Eqty ETF (JPIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs JPMorgan Diversified Return International Eqty ETF — how do they compare? Gilead Sciences, Inc. trades at $135.34 (market cap $163.51B), while JPMorgan Diversified Return International Eqty ETF trades at $73.52. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while JPMorgan Diversified Return International Eqty ETF pays none, and JPMorgan Diversified Return International Eqty ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| GILD | JPIN | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | — |
52-Week High | $155.80 | $76.96 |
52-Week Low | $108.22 | $63.14 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
JPIN, the JPMorgan Diversified Return International Equity ETF, trades at $73.33, showing minimal daily movement with a 0.08% gain. The technical outlook is neutral to bearish, with moving averages signaling caution, while oscillators remain neutral. Key support is at $72 and resistance at $73-$74. The fund, launched in 2014, provides broad exposure to international value stocks, but fundamental metrics like P/E and profitability ratios are unavailable in the provided data.
The outlook for JPIN is neutral, with technical indicators mixed and no clear directional bias. Investment opportunity lies in its diversified international equity exposure, but risks include market volatility and reliance on global economic conditions. The absence of recent fundamental data limits a comprehensive assessment, requiring investors to monitor broader market trends and fund-specific updates for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →
